Investing in prevention: what incentive does the pharmaceutical industry have?
Reynolds
Tom
T
D016588:Anticarcinogenic Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D016527:Drug Costs; D017850:Economics, Pharmaceutical; D006801:Humans; D009316:National Institutes of Health (U.S.); D009369:Neoplasms / Q000517:prevention & control*; D011322:Primary Prevention / Q000379:methods*; D012109:Research Support as Topic; D014481:United States; D014486:United States Food and Drug Administration
D016588:Anticarcinogenic Agents